Candel Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CADL research report →
Range $22 – $23
Price Chart
About the company
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer.
- CEO
- Paul-Peter Tak
- IPO
- 2021
- Employees
- 55
- HQ
- Needham, MA, US
Get TickerSpark's AI analysis on CADL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $723.18M
- P/E
- -7.00
- Fwd P/E
- 64.30
- PEG
- 0.09
- P/S
- 0.00
- P/B
- 5.80
- EV/EBITDA
- -6.88
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -89.38%
- ROIC
- -36.74%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-48,266,000
- Net Income
- $-38,182,000+30.8%
- EPS
- $-0.72+58.6%
- OCF Growth
- -41.8%
- FCF Growth
- -43.9%
- 52W High
- $14.00
- 52W Low
- $4.35
- 50D MA
- $11.46
- 200D MA
- $7.99
- Beta
- -0.47
- RSI (14)
- 36
- Avg Volume
- 1.24M
No earnings-call transcripts are available for CADL yet.
- Free Float
- 77.5%
- Shares Outstanding
- 73.27M
- Float Shares
- 56.81M
of shares held by institutions
118 13F filers
Buy/sell ratio 1.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 10.99M | ▲ 3.52K |
| Rtw Investments, LP | 6.42M | 0 |
| Blackrock, Inc. | 4.97M | ▲ 1.86M |
| State Street Corp | 3.55M | ▲ 2.73M |
| Acorn Capital Advisors, LLC | 3.50M | 0 |
| Portolan Capital Management, LLC | 3.49M | ▲ 596.07K |
| Saturn V Capital Management LLC | 3.30M | ▲ 407.10K |
| Vanguard Capital Management LLC | 2.69M | ▲ 231.28K |
| Vanguard Group Inc | 2.31M | ▲ 297.95K |
| Geode Capital Management, LLC | 1.57M | ▲ 535.59K |
| Millennium Management LLC | 1.09M | ▲ 33.82K |
| Halter Ferguson Financial Inc. | 772.46K | ▼ 131.59K |
Held by 142 ETFs
Biggest fund positions in CADL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 30, 26 | Loggia Nicoletta | other | 380 |
| Sep 30, 26 | PAPA JOSEPH C | other | 1,325 |
| Sep 30, 26 | Manning Paul B | other | 2,189 |
| Sep 10, 26 | Tak Paul Peter | other | 125,000 |
| Sep 10, 26 | Tak Paul Peter | other | 125,000 |
| Sep 10, 26 | Tak Paul Peter | sell | 220,866 |
| Sep 11, 26 | Tak Paul Peter | sell | 59,379 |
| Sep 8, 26 | Zimmermann Martine | other | 64,000 |
| Sep 8, 26 | Zimmermann Martine | other | 0 |
| Aug 17, 26 | Tyagarajan Seshu | sell | 7,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CADL coverage
Recent articles, reports, and earnings notes.
No research on CADL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CADL report →Candel Therapeutics to Present at the SITC 2026 Annual Meeting
globenewswire.com · Oct 2
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Oct 1
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI
globenewswire.com · Oct 1
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
globenewswire.com · Sep 30
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
globenewswire.com · Sep 30
Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4
seekingalpha.com · Sep 22
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
zacks.com · Sep 15
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
globenewswire.com · Sep 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.